Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Up 1.5 %

Shares of Pulmatrix stock opened at $6.00 on Friday. The stock has a market cap of $21.91 million, a P/E ratio of -2.27 and a beta of 1.54. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44. The business’s 50 day moving average is $4.28 and its 200-day moving average is $2.84.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.